The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...

Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) constitutes a frequent problem, especially in athletes showing ventricular arrhythmias with left bundle branch block ...

RIDGE is the largest non-interventional natural history and seroprevalence study of adults with PKP2-associated ARVC to date and was designed to collect and assess participants’ clinical ...

The aim of this article is to describe the pathophysiological findings that support the hypothesis of ‘exercise-induced arrhythmogenic right ventricular cardiomyopathy (ARVC)’. As mentioned, 80% of ...

The RIDGE-1 Phase 1b clinical trial of TN-401 is currently underway, aiming to enroll up to fifteen adults with PKP2-associated ARVC. Tenaya plans to report safety and biopsy data from the first ...

SAN DIEGO - Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm currently valued at $74 million, has released interim data from its RIDGE study on arrhythmogenic right ventricular ...